Use of rivaroxaban in patients with stroke

Danilo Toni, Antonio Carolei, Valeria Caso, Domenico Consoli, Massimo Del Sette, Domenico Inzitari, Maurizio Melis, Giuseppe Micieli, Leandro Provinciali, Stefano Ricci, Paola Santalucia, Vito Toso

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalNeurological Sciences
DOIs
Publication statusAccepted/In press - Feb 25 2017

Fingerprint

Stroke
Coagulants
Guidelines
Factor Xa
Transient Ischemic Attack
Cerebral Hemorrhage
Expert Testimony
Warfarin
Brain Ischemia
Atrial Fibrillation
Reperfusion
Blood Vessels
Rivaroxaban
Clinical Trials
Therapeutics
Neurologists

Keywords

  • Anti-coagulants
  • Atrial fibrillation
  • Intracerebral hemorrhage
  • Ischemic stroke
  • Rivaroxaban

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Toni, D., Carolei, A., Caso, V., Consoli, D., Del Sette, M., Inzitari, D., ... Toso, V. (Accepted/In press). Use of rivaroxaban in patients with stroke. Neurological Sciences, 1-10. https://doi.org/10.1007/s10072-017-2855-3

Use of rivaroxaban in patients with stroke. / Toni, Danilo; Carolei, Antonio; Caso, Valeria; Consoli, Domenico; Del Sette, Massimo; Inzitari, Domenico; Melis, Maurizio; Micieli, Giuseppe; Provinciali, Leandro; Ricci, Stefano; Santalucia, Paola; Toso, Vito.

In: Neurological Sciences, 25.02.2017, p. 1-10.

Research output: Contribution to journalArticle

Toni, D, Carolei, A, Caso, V, Consoli, D, Del Sette, M, Inzitari, D, Melis, M, Micieli, G, Provinciali, L, Ricci, S, Santalucia, P & Toso, V 2017, 'Use of rivaroxaban in patients with stroke', Neurological Sciences, pp. 1-10. https://doi.org/10.1007/s10072-017-2855-3
Toni D, Carolei A, Caso V, Consoli D, Del Sette M, Inzitari D et al. Use of rivaroxaban in patients with stroke. Neurological Sciences. 2017 Feb 25;1-10. https://doi.org/10.1007/s10072-017-2855-3
Toni, Danilo ; Carolei, Antonio ; Caso, Valeria ; Consoli, Domenico ; Del Sette, Massimo ; Inzitari, Domenico ; Melis, Maurizio ; Micieli, Giuseppe ; Provinciali, Leandro ; Ricci, Stefano ; Santalucia, Paola ; Toso, Vito. / Use of rivaroxaban in patients with stroke. In: Neurological Sciences. 2017 ; pp. 1-10.
@article{970596654ad44509bd9e1cd85b7d0411,
title = "Use of rivaroxaban in patients with stroke",
abstract = "Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant.",
keywords = "Anti-coagulants, Atrial fibrillation, Intracerebral hemorrhage, Ischemic stroke, Rivaroxaban",
author = "Danilo Toni and Antonio Carolei and Valeria Caso and Domenico Consoli and {Del Sette}, Massimo and Domenico Inzitari and Maurizio Melis and Giuseppe Micieli and Leandro Provinciali and Stefano Ricci and Paola Santalucia and Vito Toso",
year = "2017",
month = "2",
day = "25",
doi = "10.1007/s10072-017-2855-3",
language = "English",
pages = "1--10",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - Use of rivaroxaban in patients with stroke

AU - Toni, Danilo

AU - Carolei, Antonio

AU - Caso, Valeria

AU - Consoli, Domenico

AU - Del Sette, Massimo

AU - Inzitari, Domenico

AU - Melis, Maurizio

AU - Micieli, Giuseppe

AU - Provinciali, Leandro

AU - Ricci, Stefano

AU - Santalucia, Paola

AU - Toso, Vito

PY - 2017/2/25

Y1 - 2017/2/25

N2 - Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant.

AB - Rivaroxaban, an inhibitor of Factor Xa, is a direct oral anti-coagulant that has been found to be non-inferior to warfarin in preventing cerebral ischemia in patients with non-valvular atrial fibrillation and in the subgroup of patients with a history of the previous stroke or transient ischemic attack. Vascular neurologists in daily clinical practice may encounter patients taking rivaroxaban or patients who may benefit from its use. In this paper, we review the current clinical indications, contraindications, and clinical management guidelines for rivaroxaban while providing a special focus on neurological aspects and expert opinions on rivaroxaban therapy management in various situations that a neurologist may encounter when treating patients with an ischemic stroke (including those requiring intravenous or intra-arterial reperfusion therapy) and patients with an intracerebral hemorrhage. Since data from clinical trials and real-life data are missing in some clinical situations, strong recommendations are not always available. Nevertheless, practical guidelines should be adopted to maximize benefits from this oral anti-coagulant.

KW - Anti-coagulants

KW - Atrial fibrillation

KW - Intracerebral hemorrhage

KW - Ischemic stroke

KW - Rivaroxaban

UR - http://www.scopus.com/inward/record.url?scp=85013769552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013769552&partnerID=8YFLogxK

U2 - 10.1007/s10072-017-2855-3

DO - 10.1007/s10072-017-2855-3

M3 - Article

SP - 1

EP - 10

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -